Telomeres and telomerase: A dual role in hepatocarcinogenesis

Hepatology

Volumn 40, Issue 2, 2004, Pages 276-283

  Satyanarayana, Ande ^a   Manns, Michael P ^a   Rudolph, K Lenhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVATOR; TELOMERASE; TELOMERASE ACTIVATOR; UNCLASSIFIED DRUG;

AGING; ANIMAL CELL; ANIMAL TISSUE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CELL REGENERATION; CHROMOSOME ABERRATION; CHROMOSOME SIZE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME SYNTHESIS; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TELOMERE; TELOMERE SHORTENING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENZYME ACTIVATION; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; RNA; TELOMERASE; TELOMERE;

EID: 4043124073     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20308     Document Type: Review

References (85)

1. Blackburn E.H. Structure and function of telomeres. Nature 1991;350:569-573.
2. Vaziri H, Benchimol S. From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Exp Gerontol 1996;31:295-301.
3. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, et al. p53 deficiency rescues the adverse effects of telomere loss and co-operates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
4. Lundblad V. The end replication problem: more than one solution. Nat Med 1997;3:1198-1199.
5. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989;337:331-337.
6. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-795.
7. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-959.
8. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-68.
9. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460.
10. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992;27:383-389.
11. Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, et al. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003;124:432-444.
12. Djojosubroto MW, Choi YS, Lee HW, Rudolph KL. Telomeres and telomerase in aging, regeneration and cancer. Mol Cells 2003;15:164-175.
13. Lee HW, Blasco MA, Gottlieb GJ, Horner JW 2nd, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392:569-574.
14. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999;96:701-712.
15. Herrera E, Samper E, Martin-Caballero J, Flores JM, Lee HW, Blasco MA. Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J 1999;18:2950-2960.
16. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000;287:1253-1258.
17. Satyanarayana A, Wiemann SU, Buer J, Lauber J, Dittmar KE, Wustefeld T, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J 2003;22:4003-4013.
18. Miura N, Horikawa I, Nishimoto A, Ohmura H, Ito H, Hirohashi S, et al. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 1997;93:56-62.
19. Ide T, Tahara H, Nakashio R, Kitamoto M, Nakanishi T, Kajiyama G. Telomerase in hepatocellular carcinogenesis. Hum Cell 1996;9:283-286.
20. Kishimoto K, Fujimoto J, Takeuchi M, Yamamoto H, Ueki T, Okamoto E. Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J Surg Oncol 1998;69:119-124.
21. Toshikuni N, Nouso K, Higashi T, Nakatsukasa H, Onishi T, Kaneyoshi T, et al. Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer 2000;82:833-837.
22. Kojima H, Yokosuka O, Imazeki F, Saisho H, Omata M. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 1997;112:493-500.
23. Onishi T, Nouso K, Higashi T, Toshikuni N, Nakatsukasa H, Kobayashi Y, et al. Cellular distribution of telomerase reverse transcriptase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2003;18:1168-1174.
24. Iizuka N, Mori N, Tamesa T, Tangoku A, Oka M. Telomerase activity and Nm23-H2 protein expression in hepatocellular carcinoma. Anticancer Res 2003;23:43-47.
25. Yokota T, Suda T, Igarashi M, Kuroiwa T, Waguri N, Kawai H, et al. Telomere length variation and maintenance in hepatocarcinogenesis. Cancer 2003;98:110-118.
26. Youssef N, Paradis V, Ferlicot S, Bedossa P. In situ detection of telomerase enzymatic activity in human hepatocellular carcinogenesis. J Pathol 2001;194:459-465.
27. Hytiroglou P, Kotoula V, Thung SN, Tsokos M, Fiel MI, Papadimitriou CS. Telomerase activity in precancerous hepatic nodules. Cancer 1998;82:1831-1838.
28. Ohta K, Kanamaru T, Morita Y, Hayashi Y, Ito H, Yamamoto M. Telomerase activity in hepatocellular carcinoma as a predictor of postoperative recurrence. J Gastroenterol 1997;32:791-796.
29. Zhang R, Wang X, Guo L, Xie H. Growth inhibition of BEL-7404 human hepatoma cells by expression of mutant telomerase reverse transcriptase. Int J Cancer 2002;97:173-179.
30. Ferber MJ, Montoya DP, Yu C, Aderca I, McGee A, Thorland EC, et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003;22:3813-3820.
31. Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003;22:3911-3916.
32. Yokota T, Suda T, Igarashi M, Kuroiwa T, Waguri N, Kawai H, et al. Telomere length variation and maintenance in hepatocarcinogenesis. Cancer 2003;98:110-118.
33. Plentz R, Caselitz M, Bleck JS, Gebel M, Flemming P, Kubicka S, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatocellular carcinoma. HEPATOLOGY 2004;40:80-86.
34. Strovel JW, Abruzzo LV, Highsmith WE, Stamberg J. Quantitative measurement of telomerase activity in lymphadenopathy: correlation with histologic features and human immunodeficiency virus-1 infection. Mod Pathol 1998;11:957-962.
35. Chen Z, Smith KJ, Skelton HG 3rd, Barrett TL, Greenway HT Jr, Lo SC. Telomerase activity in Kaposi's sarcoma, squamous cell carcinoma, and basal cell carcinoma. Exp Biol Med (Maywood) 2001;226:753-757.
36. Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, et al. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer 2001;95:156-161.
37. Herbert BS, Wright WE, Shay JW. Telomerase and breast cancer. Breast Cancer Res 2001;3:146-149.
38. Itoi T, Shinohara Y, Takeda K, Nakamura K, Shimizu M, Ohyashiki K, et al. Detection of telomerase reverse transcriptase mRNA in biopsy specimens and bile for diagnosis of biliary tract cancers. Int J Mol Med 2001;7:281-287.
39. Engelhardt M, Drullinsky P, Guillem J, Moore MA. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 1997;3:1931-1941.
40. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990;346:866-868.
41. Asai A, Kiyozuka Y, Yoshida R, Fujii T, Hioki K, Tsubura A. Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res 1998;18:1465-1472.
42. van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, Cameron JL, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002;161:1541-1547.
43. Furugori E, Hirayama R, Nakamura KI, Kammori M, Esaki Y, Takubo K. Telomere shortening in gastric carcinoma with aging despite telomerase activation. J Cancer Res Clin Oncol 2000;126:481-485.
44. Bamberger CM, Else T, Bamberger AM, Frilling A, Beil FU, Allolio B, Schulte HM. Telomerase activity in benign and malignant adrenal tumors. Exp Clin Endocrinol Diabetes 1999;107:272-275.
45. Kammori M, Nakamura K, Kanauchi H, Obara T, Kawahara M, Mimura Y, et al. Consistent decrease in telomere length in parathyroid tumors but alteration in telomerase activity limited to malignancies: preliminary report. World J Surg 2002;26:1083-1087.
46. Harada K, Arita K, Kurisu K, Tahara H. Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation. Surg Neurol 2000;53:267-274.
47. Matthews P, Jones CJ, Skinner J, Haughton M, de Micco C, Wynford-Thomas D. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J Pathol 2001;194:183-193.
48. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol 2001;166:666-673.
49. Dahse R, Fiedler W, Junker K, Schlichter A, Schubert J, Claussen U. Telomerase activity and telomere lengths: alterations in renal cell carcinomas. Kidney Int 1999;56:1289-1290.
50. Alves G, Fiedler W, Guenther E, Nascimento P, Campos MM, Ornellas AA. Determination of telomerase activity in squamous cell carcinoma of the penis. Int J Oncol 2001;18:67-70.
51. Nowak R, Sikora K, Pietas A, Skoneczna I, Chrapusta SJ. Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors. Oncogene 2000;19:4075-4078.
52. Sakamoto M, Toyoizumi T, Kikuchi Y, Okamoto A, Nakayama H, Aoki D, et al. Telomerase activity in gynecological tumors. Oncol Rep 2000;7:1003-1009.
53. Thurnher D, Knerer B, Formanek M, Kornfehl J. Non-tadioactive semiquantitative testing for the expression levels of telomerase activity in head and neck squamous cell carcinomas may be indicative for biological tumour behaviour. Acta Otolaryngol 1998;118:423-427.
54. Chang JT, Liao CT, Jung SM, Wang TC, See LC, Cheng AJ. Telomerase activity is frequently found in metaplastic and malignant human nasopharyngeal tissues. Br J Cancer 2000;82:1946-1951.
55. Liao J, Mitsuyasu T, Yamane K, Ohishi M. Telomerase activity in oral and maxillofacial tumors. Oral Oncol 2000;36:347-352.
56. Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW. Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res 1997;3:619-625.
57. Trentin L, Ballon G, Ometto L, Perin A, Basso U, Chieco-Bianchi L, et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol 1999;106:662-668.
58. Wu KD, Hansen ER. Shortened telomere length is demonstrated in T-cell subsets together with a pronounced increased telomerase activity in CD4 positive T cells from blood of patients with mycosis fungoides and parapsoriasis. Exp Dermatol 2001;10:329-336.
59. Brousset P, Chaouche N, Al Saati T, Zenou RC, Delsol G. Telomerase activity in Hodgkin's disease. Leuk Lymphoma 1998;30:189-192.
60. Xu D, Zheng C, Bergenbrant S, Holm G, Bjorkholm M, Yi Q, et al. Telomerase activity in plasma cell dyscrasias. Br J Cancer 2001;84:621-625.
61. Hirashima T, Komiya T, Nitta T, Takada Y, Kobayashi M, Masuda N, et al. Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer. Anticancer Res 2000;20:2181-2187.
62. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;87:895-902.
63. Kumaki F, Kawai T, Churg A, Galateau-Salle FB, Hasleton P, Henderson D, et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 2002;26:365-370.
64. Falchetti ML, Larocca LM, Pallini R. Telomerase in brain tumors. Childs Nerv Syst 2002;18:112-117.
65. Rushing EJ, Yashima K, Brown DF, White CL 3rd, Shay JW, Risser RC, et al. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas. J Neuropathol Exp Neurol 1997;56:1142-1146.
66. Harada K, Kurisu K, Arita K, Sadatomo T, Tahara H, Tahara E, et al. Telomerase activity in central nervous system malignant lymphoma. Cancer 1999;86:1050-1055.
67. Parris CN, Jezzard S, Silver A, MacKie R, McGregor JM, Newbold RF. Telomerase activity in melanoma and non-melanoma skin cancer. Br J Cancer 1999;79:47-53.
68. Miracco C, Margherita De Santi M, Schurfeld K, Santopietro R, Lalinga AV, Fimiani M, et al,. Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity. Br J Dermatol 2002;146:399-408.
69. Stoppler H, Stoppler MC, Kisiela M, Holzbach A, Moll I, Houdek P, et al. Telomerase activity of Merkel cell carcinomas and Merkel cell carcinoma-derived cell cultures. Arch Dermatol Res 2001;293:397-406.
70. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-645.
71. Greenberg RA, Chin L, Femino A, Lee KH, Gottlieb GJ, Singer RH, et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 1999;97:515-525.
72. Gonzalez-Suarez E, Samper E, Flores JM, Blasco MA. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 2000;26:114-117.
73. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomete dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001;28:155-159.
74. Farazi PA, Glickmann J, Jiang S, Yu A, Rudolph KL, DePinho RA. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003;63:5021-5027.
75. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-649.
76. Nishida N, Nishimura T, Ito T, Komeda T, Fukuda Y, Nakao K. Chromosomal instability and human hepatocarcinogenesis. Histol Histopathol 2003;18:897-909.
77. Chang S, Khoo C, DePinho RA. Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse. Semin Cancer Biol 2001;11:227-239.
78. Wilkens L, Bredt M, Flemming P, Mengel M, Becker T, Klempnauer J, et al. Comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) in the diagnosis of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2002;9:304-311.
79. Lo AW, Sabatier L, Fouladi B, Pottier G, Ricoul M, Murnane JP. DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line. Neoplasia 2002;4:531-538.
80. Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP, et al. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer 2001;85:697-704.
81. Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F, et al. Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J 2003;22:131-139.
82. Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, et al. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001;20:7104-7109.
83. Rotman G, Shiloh Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene 1999;18:6135-6144.
84. Wong KK, Maser RS, Bachoo RM, Menon J, Carrasco DR, Gu Y, et al. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature 2003;421:643-648.
85. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002;16:935-942.